Venkatachalam Mulukutla, MD
Cardiovascular Disease · El Paso, TXNPI 1225275654
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 63.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2021 at $44,503 and has fallen 61.0% since, to $17,336 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 661 payments — averaging $236.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$99K
- W. L. Gore & Associates, Inc.$19K
- Abiomed$16K
- Abbott$7K
- Boston Scientific$7K
- Medtronic$3K
- plus $6K from 31 others
Across 1 payment — averaging $13,800 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$14K
What the payments were for
- Consulting fees$72,62546%
- Speaking & faculty fees$30,46319%
- Travel & lodging$30,09319%
- Food & beverage$23,13115%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 180 | $99,445 |
| W. L. Gore & Associates, Inc. | 17 | $19,335 |
| Abiomed | 46 | $15,539 |
| Abbott | 84 | $7,162 |
| Boston Scientific | 65 | $6,619 |
| Medtronic(2 entities) | 29 | $2,677 |
| Novartis | 60 | $924 |
| Bard Peripheral Vascular, Inc. | 7 | $819 |
| Boehringer Ingelheim | 24 | $406 |
| Johnson & Johnson | 30 | $396 |
| AstraZeneca | 16 | $383 |
| Inari Medical, Inc. | 10 | $361 |
| Pfizer | 22 | $351 |
| Amgen | 19 | $277 |
| Philips North America LLC | 6 | $272 |
| Venclose Inc. | 2 | $264 |
| Terumo Medical Corporation | 2 | $251 |
| Penumbra, Inc. | 3 | $194 |
| E.r. Squibb & Sons, L.L.C. | 11 | $176 |
| Cardiovascular Systems Inc. | 2 | $125 |
| Inspire Medical Systems, Inc. | 1 | $101 |
| Astellas Pharma US Inc | 1 | $72 |
| Novo Nordisk | 3 | $70 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $69 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Teleflex LLC | 1 | $35 |
| Chiesi USA, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Shockwave Medical, Inc | 1 | $20 |
| Heartflow, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Medicomp Inc | 1 | $14 |
| Cvrx, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$91,592
- Impella$14,828
- GORE CARDIOFORM Septal Occluder$14,142
- CARDIOFORM Septal Occluder$4,860
- Mitra Clip system$2,565
- Watchman$2,049
- CROSSBOSS$1,677
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,117
- HARMONY$1,094
- MitraClip System$833
- GENERAL VASCULAR ACCESS$718
- MitraClip$679
- TRICLIP$645
- SYNERGY$486
- SYMPLICITY G3$296
- HawkOne$292
- EVRSF$264
- MetaCross$251
- AVVIGO Guidance System$210
- TR Band$146
How this compares
$156,607 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 284 | $369,890 |
| EntrestoSacubitril/Valsartan | 94 | $143,578 |
| XareltoRivaroxaban | 74 | $85,562 |
| FarxigaDapagliflozin Propanediol | 53 | $61,666 |
| BrilintaTicagrelor | 24 | $26,593 |
| VascepaIcosapent Ethyl | 14 | $5,811 |
| Ranolazine ErRanolazine | 34 | $3,839 |
| Metoprolol Succinate | 257 | $3,013 |
| Amiodarone Hcl | 30 | $1,971 |
| ClopidogrelClopidogrel Bisulfate | 157 | $1,936 |
| Atorvastatin Calcium | 210 | $1,837 |
| Carvedilol | 236 | $1,774 |
| Lisinopril | 137 | $1,077 |
| Amlodipine Besylate | 140 | $923 |
| Olmesartan Medoxomil | 40 | $882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $351 | $369,890284 claims |
| NovartisEntresto | $924 | $143,57894 claims |
| AstraZenecaFarxiga, Brilinta | $383 | $88,25977 claims |
| Johnson & JohnsonXarelto | $396 | $85,56274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in El Paso
- David TurbayEl Paso$175K
- Juan TaverasEl Paso$91K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.